Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) is at the forefront of developing innovative respiratory support technology as an alternative to invasive mechanical ventilation. The company's flagship product, INSPIRA ART100, is a breakthrough in Augmented Respiration Technology designed to maintain optimal oxygen levels in patients without the need for intubation and sedation. This technology is particularly significant in the treatment of respiratory failure and offers a less invasive option compared to traditional mechanical ventilation.
Inspira Technologies operates in various regions, including North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The company is involved in the research, development, manufacture, and marketing of proprietary respiratory care devices, aiming to transform the landscape of acute and neonatal care.
Recently, Inspira Technologies has announced several key developments:
- April 3, 2024: Commencement of a program to explore the use of the INSPIRA ART100 Device for an artificial womb for neonates requiring vital respiratory support.
- April 10, 2024: Collaborative development with Ennocure MedTech Ltd. on bio-electronic treatment to prevent bloodstream infections in ICU patients, showcasing a 100% reduction in bacterial growth within 24 hours in an in vitro study.
- April 16, 2024: Signing of a collaboration term sheet with Beilinson Hospital for the evaluation of the INSPIRA ART100 device in organ transplant procedures.
- April 25, 2024: Receiving CSA Certification of Compliance to U.S. standards for the INSPIRA ART100 device.
- May 2, 2024: Initiation of the production of the INSPIRA ART100 medical device by a leading technology company.
- May 28, 2024: Notification of 510(k) class II clearance from the U.S. FDA for the INSPIRA ART100.
Inspira's products are designed not only to enhance patient outcomes but also to reduce the costs and complications associated with traditional respiratory support methods. The INSPIRA ART100 system has received FDA clearance, marking a pivotal moment in the company's history. Other products in the pipeline, including the INSPIRA ART (Gen 2) and HYLA™ blood sensor, are poised to further revolutionize respiratory care once approved.
News
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. receives U.S. Patent approval for orbiting blood oxygenation delivery system, a core technology of the INSPIRA ART500 device. The system is designed to revolutionize medical oxygenation by eliminating damage caused by fiber membranes. CEO Dagi Ben-Noon hails it as a monumental advancement in blood oxygenation technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.42%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has announced a non-binding Letter of Intent (LOI) with Shamir Medical Center to assess the integration and performance of the INSPIRA™ ART100 device within the hospital's clinical environment. The LOI solidifies the mutual commitment of both parties to evaluate the device's fit, efficiency, and overall impact on healthcare delivery. The collaboration aims to enhance life-support care and establish a pathway for adoption in local and international markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has announced a summary distribution agreement with Glo-Med Networks, Inc. to potentially provide $32.6 million over a 5-year period. The agreement designates Glo-Med as the exclusive distributor in Saudi Arabia, United Arab Emirates, and Bahrain for the INSPIRA™ ART devices. The agreement is subject to regulatory approvals and is seen as a significant step for both companies in broadening their range of innovative products in the healthcare market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) announces the development of a single-use disposable blood oxygenation kit for its INSPIRA ART medical device series, targeting FDA authorization in 2025. The kit is designed to be compatible with various life support machines, potentially reducing hospital costs. CEO Dagi Ben-Noon anticipates revenue streams based on the disposable razorblade business model, along with the FDA clearance of the INSPIRA™ ART100 device in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.24%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has signed a non-binding Letter of Intent with Northwestern Memorial Hospital, a top-ranked hospital in the United States, to explore collaboration for the evaluation of its INSPIRA ART100 device. The agreement is subject to FDA clearance and entering a definitive evaluation agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has closed a registered direct offering of 3,031,250 ordinary shares at a purchase price of $1.28 per share, with aggregate gross proceeds of approximately $3.88 million. The company also issued warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) has entered into a definitive agreement for the issuance and sale of 3,031,250 ordinary shares at a purchase price of $1.28 per share in a registered direct offering. The company will also issue unregistered warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (NASDAQ: IINN) Announces Breakthrough in Sensor Technology for Real-Time Blood Monitoring
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) is set to attend the 42nd Annual J.P. Morgan Healthcare Conference in January 2024. The Company's CEO and President will meet with medical device and strategic consulting companies, aiming to advance their groundbreaking life support technology. The expected FDA clearance for their innovative life support device that directly oxygenates blood is a significant milestone on the horizon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil, a distinguished specialist in cardiac surgery and intensive care medicine, is expected to significantly contribute to the deployment of the INSPIRA™ ART100. U.S. Food and Drug Administration (FDA) approval is expected in the first half of 2024. The company is leading the way in transforming life-support care, with innovative solutions that pave the way for direct blood oxygenation and AI-driven monitoring systems, potentially enhancing patient outcomes and streamlining hospital operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
FAQ
What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
The current stock price of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN) is $1.22 as of November 15, 2024.
What is the market cap of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
The market cap of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN) is approximately 22.8M.
What does Inspira Technologies do?
Inspira Technologies develops innovative respiratory support technology as an alternative to mechanical ventilation.
What is the INSPIRA ART100?
The INSPIRA ART100 is a breakthrough device designed to maintain optimal oxygen levels in patients without the need for intubation and sedation.
What regions does Inspira Technologies operate in?
Inspira Technologies operates in North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
What recent programs has Inspira Technologies announced?
Inspira has announced several key developments, including a program for neonatal respiratory support and a collaboration for bio-electronic treatment to prevent ICU infections.
Who are some of Inspira Technologies' partners?
Inspira has collaborated with Ennocure MedTech Ltd. and Beilinson Hospital among others.
Has the INSPIRA ART100 received regulatory approval?
Yes, the INSPIRA ART100 has received 510(k) class II clearance from the U.S. FDA.
What makes the INSPIRA ART100 different from traditional mechanical ventilation?
The INSPIRA ART100 rebalances oxygen levels without the need for invasive procedures, allowing patients to remain awake during treatment.
What is the significance of the CSA Certification of Compliance?
This certification indicates that the INSPIRA ART100 meets stringent safety and performance standards.
What is the financial impact of mechanical ventilation in the U.S.?
Over 600,000 patients require mechanical ventilation annually, with treatment costs estimated at $64 billion per year.
Where can I find more information about Inspira Technologies?
For more details, please visit their corporate website: https://inspira-technologies.com
Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares